Table II.
Best overall response.
|
TN (n = 22) |
R/R (n = 101) |
|
|---|---|---|
|
ORR: PR‐L or better, n (%) [95% CI] |
22 (100) [84·6–100·0] |
96 (95·0) [88·8–98·4] |
| CR, n (%) | 5 (22·7) | 16 (15·8) |
| CRi, n (%) | 0 (0) | 2 (2·0) |
| nPR, n (%) | 0 (0) | 2 (2·0) |
| PR, n (%) | 17 (77·3) | 72 (71·3) |
| PR‐L, n (%) | 0 (0) | 4 (4·0) |
| SD, n (%) | 0 (0) | 4 (4·0) |
| Discontinued prior to first assessment | 0 (0) | 1 (1·0) |
| DOR event rate, % (95% CI) | ||
| 12 months | 95·2 (70·7–99·3) | 97·8 (91·6–99·5) |
| 24 months | 85·7 (62·0–95·2) | 89·4 (80·6–94·4) |
| 36 months | 81·0 (56·9–92·4) | 86·8 (77·4–92·5) |
| 48 months | 75·2 (50·0–88·9) | 67·5 (50·4–80·3) |
| Follow‐up for DOR, months, median (range) | 44·6 (8·2+–59·7+) | 36·9 (0+–65·1+) |
CI, confidence interval; CR, complete response; CRi, CR with incomplete bone marrow recovery; DOR, duration of response; nPR, nodular partial response; ORR, overall response rate; PR, partial response; PR‐L, PR with lymphocytosis; R/R, relapsed/refractory; SD, stable disease; TN, treatment‐naïve; +, censored patient.